Compare Stocks: DMRA, CRSP, TVTX, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$51.52 +2.6%	$55.07	$44.12 ▼ $75.06	$4.86B	1.76	1.80 million shs	1.35 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$18.74 +1.7%	$25.90	$4.95 ▼ $38.33	$1.14B	1.43	726,477 shs	357,623 shs
DNTH Dianthus Therapeutics	$74.53 -0.3%	$100.75	$32.22 ▼ $117.88	$4.10B	1.35	1.00 million shs	943,572 shs
TVTX Travere Therapeutics	$52.79 -0.9%	$61.88	$22.59 ▼ $68.73	$5.02B	1.13	1.93 million shs	1.98 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+0.24%	-4.07%	-5.17%	+3.40%	-27.62%
DMRA Damora Therapeutics, Inc. Common Stock	-0.70%	-8.94%	-35.08%	-39.05%	+62.38%
DNTH Dianthus Therapeutics	-3.63%	-11.92%	-30.58%	-21.59%	+110.35%
TVTX Travere Therapeutics	+2.84%	-0.32%	-19.03%	-3.64%	+103.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$51.52 +2.6%	$55.07	$44.12 ▼ $75.06	$4.86B	1.76	1.80 million shs	1.35 million shs
DMRA Damora Therapeutics, Inc. Common Stock	$18.74 +1.7%	$25.90	$4.95 ▼ $38.33	$1.14B	1.43	726,477 shs	357,623 shs
DNTH Dianthus Therapeutics	$74.53 -0.3%	$100.75	$32.22 ▼ $117.88	$4.10B	1.35	1.00 million shs	943,572 shs
TVTX Travere Therapeutics	$52.79 -0.9%	$61.88	$22.59 ▼ $68.73	$5.02B	1.13	1.93 million shs	1.98 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+0.24%	-4.07%	-5.17%	+3.40%	-27.62%
DMRA Damora Therapeutics, Inc. Common Stock	-0.70%	-8.94%	-35.08%	-39.05%	+62.38%
DNTH Dianthus Therapeutics	-3.63%	-11.92%	-30.58%	-21.59%	+110.35%
TVTX Travere Therapeutics	+2.84%	-0.32%	-19.03%	-3.64%	+103.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.63	Moderate Buy	$65.75	27.62% Upside
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	148.13% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	74.20% Upside
TVTX Travere Therapeutics	2.75	Moderate Buy	$69.50	31.65% Upside

Current Analyst Ratings Breakdown

Latest DMRA, CRSP, TVTX, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy ➝ Neutral	$52.00
10/15/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$158.00
10/9/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/9/2026	CRSP CRISPR Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/29/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$40.00
9/28/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $60.00
9/24/2026	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$75.00 ➝ $89.00
9/23/2026	CRSP CRISPR Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/22/2026	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$76.00
9/22/2026	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$67.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$11M	452.87	N/A	N/A	$20.17 per share	2.55
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
DNTH Dianthus Therapeutics	$1.90M	2,145.01	N/A	N/A	$11.41 per share	6.53
TVTX Travere Therapeutics	$591.33M	8.41	$0.37 per share	143.04	$1.28 per share	41.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
TVTX Travere Therapeutics	-$25.55M	-$0.46	N/A	20.07	N/A	-7.35%	-55.15%	-6.88%	10/29/2026 (Estimated)

Latest DMRA, CRSP, TVTX, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	CRSP CRISPR Therapeutics	-$1.04	N/A	N/A	N/A	$14.62 million	N/A
11/5/2026	Q3 2026	DNTH Dianthus Therapeutics	-$0.9434	N/A	N/A	N/A	$0.44 million	N/A
10/29/2026	Q3 2026	TVTX Travere Therapeutics	$0.0299	N/A	N/A	N/A	$195.68 million	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
8/4/2026	Q2 2026	TVTX Travere Therapeutics	-$0.1347	-$0.10	+$0.0347	-$0.37	$157.27 million	$169.58 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
DNTH Dianthus Therapeutics	N/A	26.10	26.10
TVTX Travere Therapeutics	24.58	4.05	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
DNTH Dianthus Therapeutics	47.53%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
DNTH Dianthus Therapeutics	3.02%
TVTX Travere Therapeutics	4.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	96.69 million	91.67 million	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
TVTX Travere Therapeutics	497	94.26 million	90.08 million	Optionable

DMRA, CRSP, TVTX, and DNTH Headlines

Recent News About These Companies

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 12, 2026

October 13 at 8:21 AM | biospace.comB

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 12 at 5:00 PM | businesswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Price Target of $69.50

October 11, 2026 | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Target Price of $69.50

October 11, 2026 | marketbeat.com

Insight Wealth Strategies LLC Makes New Investment in Travere Therapeutics, Inc. $TVTX

October 9, 2026 | marketbeat.com

Travere to Present New Data Supporting FILSPARI as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

October 6, 2026 | marketscreener.comM

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

September 30, 2026 | prnewswire.com

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

September 22, 2026 | finance.yahoo.com

Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today

September 22, 2026 | finance.yahoo.com

Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's Why

September 22, 2026 | marketbeat.com

Travere Therapeutics' (TVTX) "Outperform" Rating Reaffirmed at Wedbush

September 22, 2026 | marketbeat.com

Travere Therapeutics' (TVTX) Buy Rating Reaffirmed at HC Wainwright

September 22, 2026 | marketbeat.com

Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026

September 21, 2026 | marketscreener.comM

Travere Therapeutics Announces Planned Chief Executive Officer Transition

September 21, 2026 | businesswire.com

Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing

September 18, 2026 | finance.yahoo.com

Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 Shares

September 18, 2026 | insidertrades.com